Skip to content

Cerus CERS Total Equity

Total Equity at other companies

CorMedix logo
CorMedixCRMD
$437.05M+280%
Haemonetics logo
HaemoneticsHAE
$796.32M-3.0%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$6.85B+2.6%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$655.47M-4.9%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$1.85B-38.2%
ADMA Biologics logo
ADMA BiologicsADMA
$390.33M+4.5%

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Reported directly by Cerus in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's total equity?
Cerus (CERS) reported total equity of $67.55M in Q1 2026.
How has Cerus's total equity changed year-over-year?
Cerus's total equity increased by 21.7% year-over-year, from $55.49M to $67.55M.
What is the long-term trend for Cerus's total equity?
Over 5 years (2020 to 2025), Cerus's total equity has grown at a -9.2% compound annual growth rate (CAGR), from $103.81M to $64.22M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.